Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer

Kassem Faraj, Yu Hui H. Chang, Kyle M. Rose, Elizabeth B. Habermann, David A. Etzioni, Gail Blodgett, Erik P. Castle, Mitchell R. Humphreys, Mark D. Tyson

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


INTRODUCTION: Mitomycin-C (MMC) and thiotepa are intravesical agents effective in reducing the recurrence of low-grade noninvasive bladder cancer when instilled perioperatively. No studies have compared these agents as a single-dose perioperative instillation. This study tests whether there is a difference in recurrence-free survival in patients with low-grade noninvasive bladder cancer who received intravesical MMC versus thiotepa. MATERIALS AND METHODS: A retrospective review was performed of patients who underwent cystoscopic excision of a bladder mass identified as a small, low-grade, treatment-naïve, noninvasive, wild-type urothelial carcinoma of the bladder and who received either intravesical thiotepa (30 mg/15 cc) or MMC (40 mg/20 cc) between January 1, 2002, and January 1, 2016. Data were collected for demographic characteristics, comorbid conditions, operative information, surveillance, and recurrence. The primary outcome was disease-free survival. Cohorts were compared via the doubly robust estimation approach, which used logistic regression to model the probability of recurrence. RESULTS: Of 154 total patients, 84 received intravesical MMC; 70, thiotepa. No statistical differences were shown between groups for age, sex, race, body mass index, smoking status, or baseline comorbid conditions; mass size, tumor multifocality, or tumor grade; and unadjusted recurrence rates (MMC, 36.0%; thiotepa, 46.0%; p = .33) at similar median follow up (MMC, 20.4; thiotepa, 22.8 months; p = .46). The robust logistic regression analysis yielded no differences in recurrence rates between MMC and thiotepa (OR, 0.65 [95% CI, 0.33-1.31]; p = .23). No episodes of myelosuppression or frozen pelvis were identified. CONCLUSIONS: As single-dose perioperative agents, both thiotepa and MMC were associated with similar recurrence-free survival rates.

Original languageEnglish (US)
Pages (from-to)9922-9930
Number of pages9
JournalThe Canadian journal of urology
Issue number5
StatePublished - Oct 1 2019

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer'. Together they form a unique fingerprint.

Cite this